Neurohistopathological Alterations Induced by Theobroma Cacao and Camellia Sinensis Extracts in Diabetic Male Wistar Rats.

camellia sinensis diabetic rats neurohistopathology theobroma cacao wistar rats

Journal

Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737

Informations de publication

Date de publication:
Nov 2023
Historique:
received: 11 09 2023
accepted: 08 11 2023
medline: 11 12 2023
pubmed: 11 12 2023
entrez: 11 12 2023
Statut: epublish

Résumé

Background Diabetes mellitus is often associated with neurohistopathological changes, resulting in cognitive deficits. This study aimed to explore the neurohistopathological alterations induced by Theobroma Cacao and Camellia Sinensis extracts in diabetic male Wistar rats. Methods In this randomized controlled trial, a total of 64 male Wistar rats aged between 8 and 12 weeks were allocated evenly into eight different groups. The first group, consisting of eight rats, served as the control, receiving only a standard diet with no additional treatment. The second group was treated with 150mg/kg body weight of alloxan to induce a diabetic model. The third group received a metformin treatment at a dose of 100mg/kg body weight. The fourth and fifth groups were administered with Theobroma cacao and Camellia sinensis extracts, respectively, at respective doses of 340 mg/kg and 200 mg/kg body weight. Groups six and seven were diabetic models treated with either Theobroma cacao extract (340 mg/kg) or Camellia sinensis extract (200 mg/kg). The eighth group, another diabetic model, was treated with a combination of both extracts at the same doses. Brain tissues were harvested at the end of an eight-week treatment period for histopathological evaluation. Cresyl violet staining was the method used for histopathological examination of the harvested brain tissues. Results Histopathological evaluations revealed normal neuronal structures in the control group. Alloxan-treated rats displayed significant neurodegeneration, including vacuolization and apoptosis. Metformin treatment showed moderate improvements in the neural architecture. Remarkably, Theobroma Cacao and Camellia Sinensis extracts exhibited protective effects against neurodegeneration in both non-diabetic and diabetic rats. Furthermore, a combination of both extracts in diabetic rats led to synergistic improvements in the neural structures, closely approximating normal conditions. One-way Analysis of Variance (ANOVA) revealed significant differences among the groups (F(7,56) = 24.11, p < 0.001). A Tukey post hoc test further indicated significant improvements in Metformin, Theobroma Cacao, and Camellia Sinensis-treated groups compared to the alloxan-induced diabetes model. Conclusions Both Theobroma Cacao and Camellia Sinensis extracts unveiled notable promise in countering the neurohistopathological alterations spurred by diabetes in the study. This pioneering observation accentuates the innovative possibility of utilizing these natural extracts as potential therapeutic agents for neural complications in diabetes mellitus. The compelling findings of this study contribute significantly to the existing body of research and emphatically advocate for further exhaustive exploration into the mechanistic actions of Theobroma Cacao and Camellia Sinensis extracts. The understanding gleaned from such in-depth studies could revolutionize the approach to managing and treating neural complications associated with diabetes, thereby enhancing the quality of life for affected individuals.

Identifiants

pubmed: 38073976
doi: 10.7759/cureus.48492
pmc: PMC10704851
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e48492

Informations de copyright

Copyright © 2023, Indla et al.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Diabetes Metab Res Rev. 2006 Jul-Aug;22(4):257-73
pubmed: 16506271
Brain Behav Immun. 2008 Mar;22(3):301-11
pubmed: 17951027
Curr Alzheimer Res. 2012 Jan;9(1):5-17
pubmed: 22329649
Metab Brain Dis. 2022 Apr;37(4):859-880
pubmed: 35334041
Diabetes. 2004 Feb;53(2):474-81
pubmed: 14747300
Endocr Rev. 2004 Aug;25(4):612-28
pubmed: 15294884
Diabetes Care. 2014 Jan;37 Suppl 1:S81-90
pubmed: 24357215
Lancet Neurol. 2006 Jan;5(1):64-74
pubmed: 16361024
Nutr Metab (Lond). 2012 Feb 14;9:11
pubmed: 22333133
Metab Brain Dis. 2021 Jun;36(5):1003-1014
pubmed: 33666819
Ann N Y Acad Sci. 2017 Jun;1398(1):83-98
pubmed: 28505392
Ann N Y Acad Sci. 2005 Jun;1043:598-604
pubmed: 16037282
Biochem Biophys Res Commun. 2009 Oct 16;388(2):377-82
pubmed: 19665995
Proc Natl Acad Sci U S A. 2006 Jan 24;103(4):1024-9
pubmed: 16418281
Eur J Pharmacol. 2016 Jan 5;770:16-24
pubmed: 26643169
Oxid Med Cell Longev. 2012;2012:906252
pubmed: 23150750
Front Mol Biosci. 2022 Sep 15;9:1002710
pubmed: 36188225
J Nutr. 2006 Apr;136(4):1043-7
pubmed: 16549472
Int J Mol Sci. 2020 Mar 04;21(5):
pubmed: 32143309
Diabetes. 2006 Aug;55(8):2256-64
pubmed: 16873688
World J Diabetes. 2014 Dec 15;5(6):889-93
pubmed: 25512792

Auteurs

Edward Indla (E)

Department of Anatomy, Mamata Medical College, Khammam, IND.

K V Rajasekar (KV)

Department of Radiology, Meenakshi Medical College Hospital and Research Institute, Chennai, IND.

Bandarupalli Naveen Kumar (B)

Department of Anatomy, Mamata Medical College, Khammam, IND.

S Saravana Kumar (SS)

Department of Anatomy, Meenakshi Medical College Hospital and Research Institute, Chennai, IND.

Sudhakara Chelli (S)

Department of Anatomy, MediCiti Institute of Medical Sciences, KNR university, Hyderabad, IND.

Suresh Babu Sayana (S)

Department of Pharmacology, Government Medical College and General Hospital, Suryapet, IND.

Classifications MeSH